All In Biotech

Drug Trial Radar · NCT02207699

Evaluation of the Effect of Benzonatate on QT Intervals Following Single Dose Administration of Benzonatate to Healthy Volunteers

Last checked: Nov 20, 2026Latest source record: Aug 4, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

68

Actual

Start

May 2014

Primary completion

Jul 2014

Study completion Jul 2014

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Aug 4, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Basic science
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of this study is to determine the effects of benzonatate (200 mg and 800 mg) on the QT interval following single dose oral administration at each time point post-dose.

Conditions

  • Healthy Volunteers

Interventions

  • Benzonatate 200 mgDrug

    2 benzonatate 100 mg perles and 6 placebo perles give by mouth once

  • Benzonatate 800 mgDrug

    8 benzonatate 100 mg perles given by mouth once

  • Moxifloxacin 400 mgDrug

    1 moxifloxacin 400 mg tablet given by mouth once

  • PlaceboDrug

    8 placebo perles given by mouth once

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Fridericia-corrected QTc change from the pre-dose time point to the post-dose time points following administration of study drug in therapeutic (200 mg) and supratherapeutic doses (800 mg).Time frame: -1, -0.75, -0.5, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 12, and 24 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Overland Park, Kansas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.